Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 11/20 | 0.52 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.42 |
| ▸ | INCENP | Q9NQS7 | 4/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | MGMT | P16455 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29857792 | 1.00 | SYK (0.52) | SYKMAP4K3NPC1HTTRAB9A | |
| SCHEMBL16212182 | 0.86 | HRH1 (0.42) | SYKMAP4K3NPC1HTTRAB9A | |
| SCHEMBL26916915 | 0.83 | RAB9A (0.43) | SYKMAP4K3NPC1HTTRAB9A | |
| SCHEMBL29857955 | 0.83 | RAB9A (0.43) | SYKMAP4K3NPC1HTTRAB9A | |
| SCHEMBL488302 | 0.80 | LTA4H (0.57) | MAP4K3NPC1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL9117255 | 0.78 | LTA4H (0.67) | SYKNPC1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL488392 | 0.78 | IDO1 (0.46) | NPC1HTTRAB9ASMN1; SMN2PARP10 | |
| SCHEMBL23248035 | 0.76 | ABCB1 (0.44) | SYKABCB1HTR1ADRD2AURKB | |
| SCHEMBL16211702 | 0.76 | L3MBTL1 (0.45) | HTTRAB9ASMN1; SMN2CCR5 | |
| SCHEMBL16211844 | 0.76 | KDM4E (0.43) | NPC1HTTRAB9ASMN1; SMN2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174683-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-30 | — | — | US | disclosed |
| EP-4288437-A1 | MAP4K1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2023-12-13 | — | — | EP | disclosed |
| WO-2022167627-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-08-11 | — | — | WO | disclosed |
| US-20090156578-A1 | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents | DEBIOPHARM INTERNATIONAL SA (CH) | 2009-06-18 | — | — | US | disclosed |
| US-20090156578-A1 | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents | DEBIOPHARM INTERNATIONAL SA (CH) | 2009-06-18 | — | — | US | disclosed |
| US-20090156578-A1 | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents | DEBIOPHARM INTERNATIONAL SA (CH) | 2009-06-18 | — | — | US | disclosed |
| EP-1973902-A2 | 3-HETEROCYCLYLACRYLAMIDE COMPOUNDS AS FABI INHIBITORS AND ANTIBACTERIAL AGENTS | Affinium Pharmaceuticals, Inc. (CA) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007067416-A2 | HETEROCYCLYLACRYLAMIDE COMPOUNDS AS FABI INHIBITORS AND ANTIBACTERIAL AGENTS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007067416-A2 | HETEROCYCLYLACRYLAMIDE COMPOUNDS AS FABI INHIBITORS AND ANTIBACTERIAL AGENTS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156578-A1 | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents | GAA, TFPI, DBI | SYK 805/4885MAP4K3 689/4885NPC1 1802/4885 |
| US-20240174683-A1 | MAP4K1 INHIBITORS | MAP3K4, MAP4K4, MAP4K1 | SYK 1249/4885MAP4K3 6/4885NPC1 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.